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Hypertrophic cardiomyopathy= HCM 
Internal cardioverter defibrillator= ICD 
Sudden cardiac death= SCD 
Maximal left ventricular wall thickness= MWT 
Maximal instantaneous left ventricular outflow tract gradient= LVOTgmax 
FHSCD: Family history of sudden cardiac death 
LAd: Left atrial diameter  











Implantable cardioverter defibrillators (ICD) are recommended in patients with HCM deemed to be at 
high risk of sudden cardiac death (SCD) but identification of such individuals remains challenging. In 
2014 the European Society of Cardiology (ESC) proposed a new risk stratification method based on a 
risk prediction model (HCM Risk-SCD) which estimates the 5-year risk of SCD. 
Objectives 
To externally validate the 2014 ESC recommendations in a geographically diverse cohort of HCM 
patients recruited from North America, Europe, The Middle East and Asia. 
Methods 
Observational, retrospective, longitudinal cohort study. 
Results 
The validation cohort consisted of 3703 patients. During a follow-up period of 28,186 patient years 
(median 5.9 years) 159 patients (4%) reached the SCD end-point with an annual rate of 0.6% (95% CI 
0.5, 0.7). Seventy three (2%) patients reached the SCD end-point within 5 years of follow-up, with a 
5-year incidence of 2.4% (95% CI 1.9, 3.0). Validation revealed a calibration slope of 1.02 (95% CI 
0.93 to 1.12); C-index was 0.70 (95% CI 0.68 to 0.72) and D-statistic was 1.17 (95% CI 1.05 to 1.29). 
In a complete case analysis (n= 2147; 44 SCD end-points at 5 years) patients with a predicted 5-year 
risk of <4% (n=1524; 71%) had an observed 5-year SCD incidence of 1.4% (95% CI 0.8, 2.2); 
patients with a predicted risk of ≥6% (n=297; 14%) had an observed SCD incidence of 8.9% (95% CI 
5.96, 13.1) at 5 years. There were 23 SCD end-points in patients with ≥6% SCD risk suggesting that 
for every 13 (297/23) ICD implantations in this group, 1 patient can potentially be saved from SCD at 
5 years. 
Conclusions 
HCM Risk–SCD provides accurate prognostic information and by preferentially targeting the highest 
risk group may help reduce unnecessary ICD implantation. 
Keywords: hypertrophic cardiomyopathy; sudden cardiac death; implantable cardioverter 









Hypertrophic cardiomyopathy (HCM) is a relatively common cardiac condition that can cause sudden 
cardiac death (SCD) in young and otherwise well individuals.(1,2) Prophylactic treatment with 
implantable cardioverter defibrillators (ICD) is the current standard of care for people with HCM 
deemed to be at high risk of SCD, but the identification of individuals most likely to benefit from 
device implantation remains challenging.(1,2) In 2014, the European Society of Cardiology (ESC) 
proposed a new approach to risk prediction that uses a clinical risk tool (HCM Risk-SCD) to estimate 
a five-year risk of sudden cardiac death. Although internally validated in a large multicentrecenter 
cohort,(3) papers published since the ESC recommendations have been inconsistent with respect to 
the performance of the ESC guidelines in different populations.(4-7) The aim of this study was to 
validate the 2014 ESC recommendations in a large, geographically diverse cohort recruited from 
centrecenters in North America, Europe, The Middle East and Asia. 
METHODS 
Study design 
The study used data from a retrospective, international multi-centrecenter, longitudinal cohort of 
HCM patients with HCM. The HCM Risk-SCD model was statistically validated and the clinical 
impact of the 2014 ESC SCD risk stratification guidelines examined using SCD end-points within 5 
years of baseline clinical evaluation.  
The study conforms to the principles of the Helsinki declaration. The sponsors of this study did not 
have a role in study design, data collection, analysis or interpretation. COM, RO, FJ, and PE had 
access to all data and final responsibility for submission of the manuscript. The authors from each 
participating centrecenter guarantee the integrity of data from their institution and had approval from 










The study cohort consisted of consecutively evaluated patients with HCM at 14 participating 
centrecenters in the USA, Europe, the Middle East and Asia (supplementary table 1). The patients 
were enrolled between 1970 and 2014 and none were included in the original HCM Risk-SCD 
development study.(3) Only adult patients (≥16 years of age) without prior ventricular fibrillation or 
sustained ventricular tachycardia were studied.  
HCM was defined as a maximum left ventricular wall thickness (MWT) ≥15mm unexplained by 
abnormal loading conditions(8) or in accordance with published criteria for the diagnosis of disease in 
relatives of patients with unequivocal disease.(9) Patients known to have metabolic diseases or 
syndromic causes of HCM were excluded.  
Patient assessment and data collection 
All patients had planned clinical reviews every 6-12 months or earlier if there was a change in 
symptoms. Patients underwent clinical assessment, pedigree analysis, physical examination, 
electrocardiography (resting and ambulatory) and transthoracic echocardiography. Data were 
collected independently at each participating centrecenter using the same methodology. 
Predictor variables and calculation of 5 year risk of SCD 
The following predictor variables were recorded at the time of first evaluation at each participating 
centrecenter: 
1. Age (years) 
2. Family history of SCD (FHSCD) in 1 or more first degree relatives under 40 years of age or SCD in 
a first degree relative with confirmed HCM (post or ante-mortem diagnosis) at any age. 









4. Left atrial diameter (LAd) by M-Mode or 2D echocardiography in the parasternal long axis plane 
(mm). 
5. Maximal instantaneous left ventricular outflow tract gradient (LVOTgmax) at rest and with Valsalva 
provocation (irrespective of concurrent medical treatment) using continuous wave Doppler 
echocardiography (mmHg) 
6. Non-sustained ventricular tachycardia (NSVT) defined as ≥3 consecutive ventricular beats at a rate 
of ≥120 beats per minute and <30s in duration on Holter monitoring (minimum duration 24 hours) at 
or prior to first evaluation. 
7. Unexplained syncope at or prior to first evaluation. 
The 5 year risk of SCD was calculated using the following equation: 
Index) c(Prognostiexp
5 0.9981
ˆ yearsatSCDP  
where Prognostic Index = 0.15939858*MWT - 0.00294271*MWT2 + 0.0259082* LAd + 
0.00446131*LVOTgmax + 0.4583082*FHSCD + 0.82639195*NSVT + 0.71650361*Unexplained 
syncope - 0.01799934*Age.(3) 
In keeping with clinical practice and the 2014 ESC recommendations 
(http://www.doc2do.com/hcm/webHCM.html), patients with extreme clinical characteristics who 
were under-represented in the published development cohort (left atrial diameter >67mm, left 
ventricular outflow tract gradient >154mmHg, maximal wall thickness >35mm or age >80 years) 
were not used for validation but are reported separately. The extreme clinical characteristics were 
defined a priori as  (left atrial diameter >67mm, left ventricular outflow tract gradient >154mmHg, 
maximal left ventricular wall thickness >35mm or age age >80 years. Such patients formed ≤1% of 










The study end-point was SCD or an equivalent event. SCD was defined as witnessed sudden death 
with or without documented ventricular fibrillation or death within one hour of new symptoms or 
nocturnal deaths with no antecedent history of worsening symptoms.(10) Aborted SCD during follow-
up and appropriate ICD shock therapy were considered equivalent to SCD. (11-16) ICD shocks were 
considered appropriate if the treated tachyarrhythmia was ventricular in origin as in previous 
studies.(11-16) The cause of death was ascertained by the treating cardiologists at each centrecenter 
using hospital and primary health care records, death certificates, post-mortem reports and interviews 
with witnesses (relatives and physicians). Deaths were assessed without knowledge of HCM Risk-
SCD estimates.  
General statistical methods 
All statistical analyses were carried out using STATA (version 14). Variables are expressed as mean ± 
standard deviation (SD), median (25th, 75th percentiles) or counts and percentages as appropriate. The 
follow-up time for each patient was calculated from the date of their first evaluation to the date of 
reaching the study endpoint, or death from another cause, or to the date of their most recent 
evaluation. The annual event rate was calculated by dividing the number of patients reaching the 
endpoint by the total follow-up period for that endpoint. The cumulative probability for the 
occurrence of an outcome was estimated using the Kaplan -Meier method. 
Missing data 
To determine the degree of bias due to missing data, the characteristics of patients with missing 
information were compared with those with complete information. Logistic regression was used to 
identify the predictors of missingness. Data were assumed to be missing at random and values for the 
missing predictors were imputed using multiple imputation techniques based on chained 
equations.(17) All predictors of missingness were included in the multiple imputation model, together 









hazard function.(18) A total of 45?? imputed data sets were generated and the estimates were 
combined using Rubin’s rules.(19) 
HCM Risk-SCD model validation 
The calibration slope was used to assess the degree of agreement between the observed and predicted 
hazards of SCD.(20) A value close to 1 suggests good overall agreement. Graphical comparisons of 
the observed and predicted SCD at 5 years by risk groups (group cut-offs: 0-2%, 2-4%, 4-6% and 
>6% 5-year risk of SCD) were performed. The C-index as proposed by Uno and D-statistic were used 
to measure how well the model discriminated between patients with high and low risk of SCD.(21,22) 
A value of 0.5 for C-index indicates no discrimination and a value equal to 1 indicates perfect 
discrimination. The D-statistic quantifies the observed separation between subjects with low and high 
predicted risks as predicted by the model and can be interpreted as the log hazard ratio for having 
SCD between the low and high risk groups of patients. A model with no discriminatory ability has  
will produce a value of 0 for D-statistic, with increasing values indicating greater separation.  
Sensitivity analysis: septal reduction therapy 
Additional model validation was performed after excluding patients undergoing septal reduction 
therapy. Patients with drug refractory symptoms secondary to outflow tract obstruction frequently 
undergo septal reduction therapy after baseline assessment Septal reduction therapy (myectomy or 
alcohol septal ablation which ) can potentially decreasereduce SCD risk predictions by relieving 
LVOTgmax, and reducing MWT and LA size which are predictors of SCD risk. (3)  To assess the 
impact of septal reduction therapy on the predictive performance of the model, HCM Risk-SCD was 
validated without patients undergoing septal reduction therapy within 5 years of follow-up. 
Complete case analysis: HCM Risk-SCD and SCD end-points at 5 years  
The incidence of the SCD end-point is reported in patients with all the necessary data required to 









≥6%) based on the calculated 5-year SCD risk and the 2014 ESC guideline recommendations. The 
clinical implications of ICD implantation with a threshold of ≥4%, ≥5% and ≥6% were examined by  
descriptive statisticscalculating the number-needed-to-treat to prevent one SCD end-point. 
RESULTS 
Clinical characteristics of the cohort 
The study enrolled a total of 3902 patients including 199 (5%) with extreme clinical characteristics. 
The validation cohort consisted of 3703 patients; and the baseline clinical characteristics are shown in 
table 1. One hundred and fifty-one patients (4%) were diagnosed on the basis of familial criteria.(9) 
During follow-up, 397 (11%) patients received an ICD. 
SCD end-points during follow-up 
During a follow-up period of 28,186 patient years (median 5.9 (3.0, 10) years; range 2 days [SCD 
end-point] to 39.6 years [censored]), 159 patients (4%) reached the SCD end-point with an annual rate 
of 0.6% (95% CI: 0.5, 0.7). Appropriate ICD shocks contributed 42 SCD end-points (26%). Seventy 
three (2%) patients reached the SCD end-point within 5 years of follow-up, with a 5-year incidence of 
2.4% (95% CI: 1.9, 3.0). The clinical characteristics of patients with and without the SCD end-point 
are shown in table 2. 
Missing data 
Missing data were observed in six of the seven HCM Risk-SCD predictor variables: NSVT 30%, 
LVOTgmax 17%, unexplained syncope 2%, FHSCD 2%, LAd 10% and MWT 0.8%. Complete data for 
the calculation of HCM Risk-SCD estimates were available in 2147 (58%) patients. Missingness was 
associated with systolic blood pressure, alcohol septal ablation, myectomy, ethnicity, NYHA III/IV, 











Validation revealed a calibration slope of 1.017 (95% CI: 0.893 to 1.142) 1.022 (95% CI 0.9328 to 
1.1216). Figure 1 illustrates a good agreement between the observed and predicted risk of sudden 
cardiac death at 5 years, particularly in the low risk groups. The C-index was 0.698 (95% CI: 0.671 to 
0.725) 0.70697 (95% CI 0.6875 to 0.7219). The D-statistic was 1.165 (95% CI: 1.004 to 1.327) 
1.1766 (95% CI 1.0546 to 1.2985) suggesting that the hazard of SCD is 3.2 times higher in the high 
risk group compared to the hazard in the low risk group as predicted by the model. 
Sensitivity analysis: septal reduction therapy 
A total of 670 (18%) patients had septal reduction therapy at some point during their clinical course 
(542 myectomies and 150 alcohol septal ablations, with 22 patients having both procedures) and most 
(85%) were low or intermediate risk. The baseline clinical characteristics are shown in table 4. During 
follow-up 20 patients who had septal reduction therapy reached the SCD end-point with an annual 
rate of 0.4% (95% CI 0.3, 0.6) post septal reduction therapy. Of the 518 patients who had septal 
reduction therapy within 5 years of first evaluation, 85% were low or intermediate risk and , 8 (1.5%) 
reached the SCD end-point within that period. The calibration slope for the model after excluding 
patients with septal reduction therapy within 5 years of baseline evaluation was 1.090.98 (95% CI: 
0.9985, 1.118), the C-index was 0.7169 (95%: CI 0.668, 0.723) and D-statistic was 1.172 (95% CI: 
1.00.95, 1.295). 
Complete case analysis: HCM Risk-SCD and SCD end-points at 5 years 
The 2147 (58%) patients with complete data had a median 5-year risk of SCD of 2.6% (1.7, 4.4). 
During a follow-up period of 14,496 years (median 5.4 (2.8, 8.5) years) a total of 96 SCD end-points 
were observed and 44 patients reached the SCD end-point within 5 years (figure 2). The majority 
(28/44; 64%) of SCD end-points within 5 years of baseline evaluation occurred in patients with a 5-









had a median predicted 5-year SCD risk of 2.6% (1.7%, 4.3%), whilst the corresponding calculated 
risk figures for those reaching the SCD end-point (n=44) wasere 6.2% (3.2%, 8.6%).  
For every 22 ICD implantations in patients with ≥4% 5-year SCD risk, 1 patient can potentially be 
saved from SCD at 5 years. At an ICD implantation threshold of ≥5 and ≥6%, 1 patient can 
potentially be saved for every 16 and 13 ICD implantations respectively. Of the 623 patients with 
≥4% SCD risk at 5 years, 28 experienced a SCD end-point which suggests that for every 22 (623/28) 
ICD implantations in this group, 1 patient can potentially be saved from SCD in that time period. Of 
the 428 patients with ≥5% SCD risk at 5 years, 27 experienced a SCD end-point which suggests that 
for every 16 (428/27) ICD implantations, 1 patient can potentially be saved from SCD at 5 years. Of 
the 297 patients with ≥6% SCD risk at 5 years, 23 experienced a SCD end-point suggesting that for 
every 13 (297/23) ICD implantations in this group of patients, 1 patient can potentially be saved from 
SCD at 5 years. Of the 1524 patients with <4% SCD risk at 5 years, 16 experienced a SCD end-point 
suggesting that for every 95 (1524/16) patients not implanted an ICD, 1 can potentially die suddenly 
within 5 years. 
SCD end-points in patients with extreme clinical characteristics 
A group of 199 patients (199/3902; 5%) had extreme clinical characteristics, including This group 
included 111 patients aged >80years, 31 patients with LVOTgmax >154mmHg, 28 patients with LAd 
>67mm and 34 patients with MWT>35mm (5 patients had more than one outlying clinical 
characteristic). The baseline clinical characteristics of these patients are shown in table 1. 
During a follow-up period of 1,102 patient years (median 4.5 (2.1, 7.5) years; range 6 days [SCD end-
point] to 24.0 years [censored]), 16 patients (8%) reached the SCD end-point. Nine (4%) patients 
reached the SCD end-point within 5 years of baseline assessment. The annual rate of SCD end-point 
was 1.5% (95% CI: 0.9, 2.4) with a 5-year cumulative incidence of 5.9% (95% CI: 3.0, 11.1). 
Appropriate ICD shocks did not contribute to SCD end-points. Seven (7/16; 44%) SCD end-points 









Complete data to calculate HCM Risk-SCD were available in 109 (65%) patients with extreme 
clinical characteristics. Of the 74 (637%) patients with a 5-year risk of <4%, two reached the SCD 
end-point within 5 years of baseline assessment (aged 82 and 47 years, both with significant left 
ventricular outflow tract obstruction).There were no SCD end-points within 5 years of evaluation in 
21 (11%) high risk patients (with a ≥6% 5-year risk) or in the 14 (7%) intermediate risk patients  with 
a (4% to <6% 5-year risk). Of the 74 (37%) patients with a 5-year risk of <4%, two reached the SCD 
end-point within 5 years of baseline assessment (aged 82 and 47 years, both with significant left 
ventricular outflow tract obstruction).  
MWT>35mm was present in 34 patients (mean age 41±18 years, 19 (56%) male). During a follow-up 
period of 271 patient years (median 7.1 (4.1, 12.1) years), 4 patients reached the SCD end-point. 
There was a single SCD end-point within 5 years of assessment with a 5 year incidence of 3.2% (95% 
CI: 0.5, 21). None of the patients with a All MWT>35mm  patients who reached the SCD end-point 
did not hadve sufficient data to calculate the 5 year risk of SCD.  
DISCUSSION 
The clinical usefulness of the 2014 ESC guidelines for sudden death prevention is dependent on the 
performance of the HCM Risk-SCD tool and external validation studies are essential to demonstrate 
the accuracy of its predictions in diverse patient populations outside the original development cohort. 
This study demonstrates that HCM Risk-SCD provides reasonably accurate SCD risk estimates in 
patients recruited in multiple different localities around the World and illustrates . The study also 
shows the positive clinical impact of the 2014 ESC recommendations on clinical decision making 
ICD implantation by targeting the highest risk group and attempting to minimise unnecessary ICD 
implantation. 
In this external validation study, HCM Risk-SCD performance was similar to that reported in the 
original study and is consistent n keeping with other several smaller external validation studies in 









American centrecenters in which, HCM Risk-SCD had a high negative predictive value but was less 
reliable in predicting long term outcomes.(7) However, direct comparison with the present analysis 
other studies is difficult as the North American study did not report discrimination, calibration or end-
points within 5 years of baseline evaluation.(7) 
This study shows that the model allows effective clinical decision making. This study shows that 
HCM Risk-SCD can be used to avoid unnecessary ICD implants in low risk patients. The large 
majority of HCM patients in this study had a 5-year risk of SCD of <4% and the very low SCD end-
point rate in this patient subgroup, reported in this and other studies,(4,5,7) supports the 2014 ESC 
recommendation not to implant an ICD in individuals with a low estimated risk.(2) Conversely, 
patients with a predicted 5-year risk of SCD ≥6% formed a small subgroup which had the highest 
event rate and the largest absolute number of events .(2) In patients with a high estimated 5 year risk, 
the predicted event rates were slightly overestimated, but this is less of a problem in clinical practice 
as this group of patients still had the highest event rate (≥6% at 5 years) and as a result the greatest 
potential benefit from prophylactic ICD therapy.. Targeting of this group for prophylactic ICD 
therapy prevents unnecessary ICD implantation and is likely to yield greatest long-term benefit..   
Since there is no consensus on the absolute SCD risk that justifies ICD therapy, there are some 
patients in whom clinical decision making is more complex and determined by more than an 
estimation of SCD risk. This is reflected in the 2014 ESC guidelines in the form of an intermediate 
risk category (5-year risk of ≥4% to <6%) in which an ICD may be considered following a detailed 
clinical assessment and an appraisal of the lifelong risks and benefits of device therapy. This study 
shows that ICDs have the potential to prevent some sudden deaths in this subgroup, especially in 
those with a 5-year risk of ≥5%. Approximately one in seven patients had intermediate risk (5-year 
risk of ≥4% to <6%) which, depending on individual clinical characteristics and social context, might 
justify consideration of an ICD. This eventuality was recognised in the 2014 ESC guidelines and this 
study shows that ICDs have the potential to prevent some sudden deaths in this subgroup, especially 









implantation is the greater healthcare cost and unnecessary exposure of individual patients to the long-
term complications of devicesThe downside of using a lower risk threshold for ICD implantation is a 
higher number-needed-to-treat with its attendant effects on healthcare cost and individual exposure to 
the long-term effects of device implantation. 
PHCM patients with extreme values for individual risk factors were underrepresented in the original 
HCM Risk-SCD development cohort(3) and consequently the 2014 ESC guidelines do not 
recommend use of the model in such patients.(2) Patients with extreme clinical characteristics were 
uncommon in this study which implies that the 2014 ESC guidelines are applicable to most patients 
seen in clinical practice. Furthermore, most were >80 years of age, a group in whom ICD implantation 
is frequently inappropriate due to co-morbid conditions.  
Patients undergoing septal reduction therapy were more frequent in this study (18%) than in the 
development cohort (9%).(3) Even though septal reduction therapy may have an impact on disease 
outcomes, the sensitivity analysis in this study suggests that the accuracy of HCM Risk-SCD 
predictions is not significantly affected by septal reduction therapy in the short term. These data 
suggest that SCD risk stratification should be undertaken independently but in parallel with the 
management of symptomatic left ventricular outflow tract obstruction. 
As with other widely used clinical risk tools, it is essential that HCM Risk-SCD and the 2014 ESC 
guidelines continue to be the subject of constant reassessment in diverse patient populations to ensure 
accuracy in varied clinical scenarios. Risk stratification Even though no risk stratification strategy will 
ever be able to predict SCD with absolute certainty, risk prediction can potentially be further 
improved by examining the incremental predictive value of other patient characteristics such as 
genotype and myocardial scar burden in future studies.(23,24) Despite the promise of future 
improvements there will always be inherent uncertainty exemplified by sudden deaths in apparently 
low risk patients and lack of events in high risk patients with past and present risk stratification 









quantification of risk enhances the shared decision making process and may aid the development of an 
effective decision making tool in the future.(27) 
This study has a number of limitations. A retrospective design was essential since the low SCD rate 
makes prospective validation studies challenging as large number of patients need to be followed up 
for prolonged time periods. This validation study had more missing data that the original development 
study but appropriate statistical techniques were used to overcome this problem. 
CONCLUSIONS 
This external validation study shows that the HCM Risk-SCD model and 2014 ESC guidelines 
provide accurate prognostic information in patients with HCM which can be used to identify patients 
with a high risk of potentially fatal ventricular arrhythmia in the short to medium termThis external 
validation study shows that HCM Risk–SCD provides accurate prognostic information in patients 
with HCM. The framework set out by the 2014 ESC guidelines preferentially targets the highest risk 
group and helps reduce unnecessary ICD implantation.. While no risk stratification strategy can 
predict all events, quantification of risk enhances the shared decision making process and provides the 















Competency in medical knowledge 1: 
Hypertrophic cardiomyopathy (HCM) in an inherited disease associated with sudden cardiac death 
(SCD) secondary to ventricular fibrillation. An Implantable Cardioverter Defibrillator (ICD) is 
recommended for secondary prevention in survivors of sudden death and for primary prevention in 
high risk patients. 
Competency in medical knowledge 2: 
All patients with HCM should undergo SCD risk stratification with a family pedigree, ambulatory 
ECG monitoring and a transthoracic echocardiogram. 
Competency in patient care: 
The 2014 ESC guidelines recommend stratification using a risk prediction model (HCM Risk-SCD) 
which uses 7 readily available clinical parameters (maximal wall thickness, non-sustained ventricular 
tachycardia, family history of SCD, left atrial diameter, left ventricular outflow tract gradients, age, 
unexplained syncope) to estimate the 5-year risk of SCD. 
Competency in interpersonal skills and communication skills: 
It is important to discuss with HCM patients the risk of SCD and the uncertainties of risk 
stratification. 
Translational outlook 1: 
This study demonstrates that HCM Risk-SCD provides accurate SCD risk estimates in patients 
recruited in different localities around the World. Most HCM patients are low risk and require regular 
reassessment. Most SCD occur in patients with a 5-year risk of >6%. 









Additional research is needed to improve SCD risk stratification by examining the incremental 




This work was undertaken at University College London (UK) (London, UK) which received a 
proportion of funding from the United Kingdom Department of Health's National Institute for Health 
Research Biomedical Research Centres funding scheme and St Bartholomew’s Hospital, London. P 
Garcia Pavia was supported by Instituto de Salud Carlos III [grants  PI14/0967 and 
RD012/0042/0066] through the Plan Estatal de I+D+I 2013-2016 – European 
Regional Development Fund (FEDER) “A way of making Europe”.  
To be completed 
 
CONFLICTS OF INTEREST 

















 1.  Gersh BJ, Maron BJ, Bonow RO et al. 2011 ACCF/AHA Guideline for the Diagnosis and 
Treatment of Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American 
College of Cardiology Foundation/American Heart Association Task Force on Practice 
Guidelines. Circulation 2011;124:2761-2796. 
 2.  Elliott PM, Anastasakis A, Borger MA et al. 2014 ESC Guidelines on diagnosis and 
management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and 
Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). 
Eur Heart J 2014;35:2733-2779. 
 3.  O'Mahony C, Jichi F, Pavlou M et al. A novel clinical risk prediction model for sudden 
cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD). Eur Heart J 2014;35:2010-
2020. 
 4.  Vriesendorp PA, Schinkel AF, Liebregts M et al. Validation of the 2014 European Society of 
Cardiology Guidelines Risk Prediction Model for the Primary Prevention of Sudden Cardiac 
Death in Hypertrophic Cardiomyopathy. Circ Arrhythm Electrophysiol 2015;8:829-835. 
 5.  Fernandez A, Quiroga A, Ochoa JP et al. Validation of the 2014 European Society of 
Cardiology Sudden Cardiac Death Risk Prediction Model in Hypertrophic Cardiomyopathy in 
a Reference Center in South America. Am J Cardiol 2016;118:121-126. 
 6.  Magri D, Limongelli G, Re F et al. Cardiopulmonary exercise test and sudden cardiac death 









 7.  Maron BJ, Casey SA, Chan RH, Garberich RF, Rowin EJ, Maron MS. Independent 
Assessment of the European Society of Cardiology Sudden Death Risk Model for 
Hypertrophic Cardiomyopathy. Am J Cardiol 2015;116:757-764. 
 8.  Elliott P, Andersson B, Arbustini E et al. Classification of the cardiomyopathies: a position 
statement from the european society of cardiology working group on myocardial and 
pericardial diseases. Eur Heart J 2008;29:270-276. 
 9.  McKenna WJ, Spirito P, Desnos M, Dubourg O, Komajda M. Experience from clinical 
genetics in hypertrophic cardiomyopathy: proposal for new diagnostic criteria in adult 
members of affected families. Heart 1997;77:130-132. 
 10.  Elliott PM, Poloniecki J, Dickie S et al. Sudden death in hypertrophic cardiomyopathy: 
identification of high risk patients. J Am Coll Cardiol 2000;36:2212-2218. 
 11.  Olivotto I, Gistri R, Petrone P, Pedemonte E, Vargiu D, Cecchi F. Maximum left ventricular 
thickness and risk of sudden death in patients with hypertrophic cardiomyopathy. J Am Coll 
Cardiol 2003;41:315-321. 
 12.  Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M, McKenna WJ. Non-sustained 
ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden 
death risk in young patients. J Am Coll Cardiol 2003;42:873-879. 
 13.  Maron MS, Olivotto I, Betocchi S et al. Effect of Left Ventricular Outflow Tract Obstruction 









 14.  Adabag AS, Casey SA, Kuskowski MA, Zenovich AG, Maron BJ. Spectrum and prognostic 
significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic 
cardiomyopathy. J Am Coll Cardiol 2005;45:697-704. 
 15.  Gimeno JR, Tome-Esteban M, Lofiego C et al. Exercise-induced ventricular arrhythmias and 
risk of sudden cardiac death in patients with hypertrophic cardiomyopathy. Eur Heart J 
2009;30:2599-2605. 
 16.  Efthimiadis GK, Parcharidou DG, Giannakoulas G et al. Left ventricular outflow tract 
obstruction as a risk factor for sudden cardiac death in hypertrophic cardiomyopathy. Am J 
Cardiol 2009;104:695-699. 
 17.  van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure 
covariates in survival analysis. Stat Med 1999;18:681-694. 
 18.  White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and 
guidance for practice. Stat Med 2011;30:377-399. 
 19.  Rubin D. Multiple imputation for nonresponse in surveys.  New York: John Wiley and Sons, 
1987. 
 20.  Steyerberg EW. Clinical prediction models. A practical approach to development, validation 
and updating. 1st ed. New York: Springer Science+Business Media, 2009. 










 22.  Gonen M, Heller G. Concordance probability and discriminatory power in proportional 
hazards regression. Biometrika 2005;92:965-970. 
 23.  Lopes LR, Syrris P, Guttmann OP et al. Novel genotype-phenotype associations demonstrated 
by high-throughput sequencing in patients with hypertrophic cardiomyopathy. Heart 
2015;101:294-301. 
 24.  Weng Z, Yao J, Chan RH et al. Prognostic Value of LGE-CMR in HCM: A Meta-Analysis. 
JACC Cardiovasc Imaging 2016. 
 25.  O'Mahony C, Esteban MTT, Lambiase PD et al. A validation study of the 2003 American 
College of Cardiology/European Society of Cardiology and 2011 American College of 
Cardiology Foundation/American Heart Association risk stratification and treatment 
algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy. Heart 
2013;99:534-541. 
 26.  Chan RH, Maron BJ, Olivotto I et al. Prognostic value of quantitative contrast-enhanced 
cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with 
hypertrophic cardiomyopathy. Circulation 2014;130:484-495. 
 27.  Elwyn G, Frosch D, Thomson R et al. Shared decision making: a model for clinical practice. J 
Gen Intern Med 2012;27:1361-1367. 
 
  Con formato: Sangría: Izquierda:  0 cm, Sangría francesa: 
1,27 cm, Espacio Después:  0 pto, Punto de tabulación:  0,95










Figure 1. Calibration by risk group. 
Circles represent observed and diamonds represent predicted probabilities of sudden cardiac death in 
5 years using a random multiple imputation dataset. The four risk groups (1-4) were created using 
model-based predicted probabilities (0-2%, 2-4%, 4-6% and >6% 5-year risk of SCD). These groups 
are selected for the purposes of validation rather than clinical decision making. 
Figure 2: Kaplan-Meier curve showing SCD end-points within 5 years of baseline evaluation, 
stratified according to the estimated 5 year risk of SCD. 
Patients with complete data for the calculation of HCM Risk-SCD estimates (n= 2147) were classified 
in three risk groups in accordance to the 2014 ESC guidelines (HCM Risk-SCD <4%, 4% to <6%, 
≥6%). The at-risk table shows the number of SCD end-points in parentheses.  
Figure 3: The relative contribution of each risk group to SCD end-points 
Patients with complete data for the calculation of HCM Risk-SCD estimates (n= 2147) were classified 
in three risk groups in accordance to the 2014 ESC guidelines (HCM Risk-SCD <4%, 4% to <6%, 










Table 1: Baseline clinical characteristics 
























Number of patients 3703 199 3675 
Male 2241 (61%) 89 (45%) 2349 (64%) 
Age; years 52 ±15 70 ±19 48 ±17 
NYHA III/IV 660 (19%) 63 (32%) 426 (12%) 
Prior Myectomy 77 (2%) 5 (3%) 34 (1%) 
Prior Alcohol septal ablation 23 (0.6%) 0 10 (0.3%) 
Amiodarone 297 (8%) 17 (9%) 468 (13%) 
ICD 123 (3%) 7 (4%) 42 (1%) 
Permanent /persistent AF 433 (12%) 34 (17%) 366 (10%) 
NSVT 582 (22%) 39 (31%) 634 (17%) 
LA diameter; mm 43±8 49±12 44±8 
LVOTgmax; mmHg 11 (7, 55) 36 (9,100) 12 (5, 49) 
LVedd; mm 45±7 44±7 45±7 
MWT; mm 20±4 23±8 20±5 
FS; % 42±10 43±11 41±9 
FHSCD; n (%) 620 (17%) 19 (10%) 886 (24%) 
Unexplained syncope; n (%) 474 (13%) 31 (16%) 507 (14%) 
NYHA: New York Heart Association, ICD: implantable cardioverter defibrillator, AF: Atrial fibrillation, NSVT: non-
sustained ventricular tachycardia, LA: left atrium, LVOTgmax: maximal instantaneous left ventricular outflow tract gradient 
at rest or Valsalva, LVedd: left ventricular end diastolic dimension, MWT: maximal wall thickness, FS: fractional 
shortening, FHSCD: family history of sudden cardiac death, SCD: sudden cardiac death.*HCM Risk-SCD is currently not 
recommended in patients underrepresented in the development cohort (left atrial diameter>67mm, left ventricular outflow 









Table 2: The baseline clinical characteristics of patients with and without the SCD end-point at 






Patients with SCD 
end-points within 5 
years n=73 (2%) 
Male 2196 (61%) 45 (62%) 
Age; years 52±15 46±15 
NYHA III/IV 647 (19%) 13 (18%) 
Myectomy 76 (2%) 1 (1%) 
Alcohol septal ablation 21 (0.6%) 2 (3%) 
Amiodarone 279 (8%) 18 (25%) 
Permanent /persistent AF 415 (12%) 18 (25%) 
NSVT 558 (22%) 24 (44%) 
LA diameter; mm 43±8 44±7 
LVOTGmax; mmHg 12 (7, 55) 11 (9, 73) 
LVedd; mm 45±7 46±7 
MWT; mm 20±4 22±5 
FS; % 42±10 43±12 
FHSCD 600 (17%) 20 (27%) 
Unexplained syncope 457 (13%) 17 (23%) 
NYHA: New York Heart Association, ICD: implantable cardioverter defibrillator, AF: Atrial 
fibrillation, NSVT: non-sustained ventricular tachycardia, LA: left atrium, LVOTgmax: maximal 
instantaneous left ventricular outflow tract gradient at rest or Valsalva, LVedd: left ventricular end 
diastolic dimension, MWT: maximal wall thickness, FS: fractional shortening, FHSCD: family 










Table 3: Events in patients with complete dataset to calculate HCM Risk-SCD 
 Calculated HCM Risk-SCD at 5 years in 2147 patients 
Risk category <4% 4% to <6% ≥6% 
2014 ESC guideline 
recommendation on ICD 
implantation 
Not recommended if there are no other 
clinical features that are of proven prognostic 
importance (III, B)  
 
May be considered in 
individual patients (IIb, B) 
Should be considered (IIa, B) 
Number of patients 1524 (71%) 326 (15%) 297 (14%) 
SCD end-points within 5 years 16 (1%) 5* (1.5%) 23 (7%) 
5 year incidence of SCD 1.4% (95% CI: 0.8, 2.2) 1.8% (95% CI: 0.7, 4.3) 8.9% (95% CI: 5.96, 13.1) 
















Patients with septal 
reduction therapy 
prior to first 
evaluation (n=98) 




Time interval between septal 
reduction and baseline 
evaluation (years) 
NA 2.2 (0.4, 8.0) 0.11 (0.01, 1.3) 
Male 1883 (62%) 44 (45%) 314 (55%) 
Age; years 52±15 52±15 51±14 
NYHA III/IV 319 (11%) 27 (26%) 315 (55%) 
Amiodarone 216 (7%) 21 (22%) 60 (10%) 
Permanent /persistent AF 380 (13%) 19 (21%) 34 (6%) 
NSVT 494 (22%) 21 (37%) 67 (22%) 
LA diameter; mm 43±8 47±9 47±8 
LVOTGmax; mmHg 8 (6, 35) 17 (8, 72) 64 (29, 100) 
LVedd; mm 45±7 45±7 43±7 
MWT; mm 19±4 19±5 21±4 
FS; % 41±10 40±13 45±9 
FHSCD 508 (17%) 18 (19%) 94 (17%) 
Unexplained syncope 364 (12%) 12 (13%) 98 (18%) 
NYHA: New York Heart Association, ICD: implantable cardioverter defibrillator, AF: Atrial fibrillation, 
NSVT: non-sustained ventricular tachycardia, LA: left atrium, LVOTgmax: left ventricular outflow tract gradient 
at rest or Valsalva, LVedd: left ventricular end diastolic dimension, MWT: maximal wall thickness, FS: 












Figure 1. Calibration by risk group. 
Circles represent observed and diamonds represent predicted probabilities of sudden cardiac death in 
5 years using a random multiple imputation dataset. The four risk groups (1-4) were created using 
model-based predicted probabilities (0-2%, 2-4%, 4-6% and >6% 5-year risk of SCD). These groups 




























Figure 2: Kaplan-Meier curve showing SCD end-points within 5 years of baseline evaluation, 
stratified according to the estimated 5 year risk of SCD. 
Patients with complete data for the calculation of HCM Risk-SCD estimates (n= 2147) were classified 
in three risk groups in accordance to the 2014 ESC guidelines (HCM Risk-SCD <4%, 4% to <6%, 


































297 265(9) 248(3) 227(6) 218(2) 188(3)>=6%
326 299(1) 271(1) 242(3) 223(0) 198(0)4 to <6%
1524 1390(7) 1249(1) 1106(2) 973(2) 814(4)<4%
Number at risk
0 1 2 3 4 5
Follow-up (years)
<4% 4% to <6% =>6%
Complete case analysis n=2147 patients











Figure 3: The relative contribution of each risk group to SCD end-points 
Patients with complete data for the calculation of HCM Risk-SCD estimates (n= 2147) were classified 
in three risk groups in accordance to the 2014 ESC guidelines (HCM Risk-SCD <4%, 4% to <6%, 
≥6%). Even though only 14% of patients have a HCM-Risk SCD ≥6%, these patients contribute 52% 
of SCD end-points. 
 
 
 
P
ag
e3
5
 
 
 
 
 
